Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Regeneron is facing two FDA decisions for its T-cell engagers.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
